Literature DB >> 11996607

Rifampin and rifabutin drug interactions: an update.

Christopher K Finch1, Cary R Chrisman, Anne M Baciewicz, Timothy H Self.   

Abstract

Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes. A few examples of well-documented clinically significant interactions include interactions with warfarin, oral contraceptives, cyclosporine, glucocorticoids, ketoconazole or itraconazole, theophylline, quinidine sulfate, digitoxin or digoxin, verapamil hydrochloride, human immunodeficiency virus-related protease inhibitors, zidovudine, delavirdine mesylate, nifedipine, and midazolam. Recent reports have demonstrated clinically relevant interactions with numerous other drugs, such as buspirone hydrochloride, zolpidem tartrate, simvastatin, propafenone hydrochloride, tacrolimus, ondansetron hydrochloride, and opiates. Rifabutin reduces serum concentrations of antiretroviral agents, but less so than rifampin. To avoid a reduced therapeutic response, therapeutic failure, or toxic reactions when rifampin is added to or discontinued from medication regimens, clinicians need to be cognizant of these interactions. Enhanced knowledge of known interactions will continue to develop, including research on the induction of specific cytochrome P-450 isoenzymes and on the importance of the P-glycoprotein transport system. New rifampin and rifabutin interactions will be discovered with further investigations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11996607     DOI: 10.1001/archinte.162.9.985

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  36 in total

Review 1.  [Cytochrom-P450 mediated drug interactions caused by antibiotics].

Authors:  Christiane Thallinger; Christian Joukhadar
Journal:  Wien Med Wochenschr       Date:  2006-09

Review 2.  Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU.

Authors:  Isabel Spriet; Wouter Meersseman; Jan de Hoon; Sandrina von Winckelmann; Alexander Wilmer; Ludo Willems
Journal:  Intensive Care Med       Date:  2009-01-09       Impact factor: 17.440

3.  Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers.

Authors:  Yao Chen; Wei Zhang; Wei-hua Huang; Zhi-rong Tan; Yi-cheng Wang; Xi Huang; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2013-07-07       Impact factor: 2.953

Review 4.  Nontuberculous mycobacteria infection in solid organ transplant recipients.

Authors:  C Piersimoni
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-07       Impact factor: 3.267

Review 5.  Clinical Guidance for Managing Statin and Antimicrobial Drug-Drug Interactions.

Authors:  Leigh Anne Hylton Gravatt; Rachel W Flurie; Estela Lajthia; Dave L Dixon
Journal:  Curr Atheroscler Rep       Date:  2017-10-09       Impact factor: 5.113

Review 6.  Psychotropic drug-drug interactions involving P-glycoprotein.

Authors:  Yumiko Akamine; Norio Yasui-Furukori; Ichiro Ieiri; Tsukasa Uno
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

7.  The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.

Authors:  Tanuja N Gengiah; Nicholas H G Holford; Julia H Botha; Andrew L Gray; Kogieleum Naidoo; Salim S Abdool Karim
Journal:  Eur J Clin Pharmacol       Date:  2011-11-23       Impact factor: 2.953

Review 8.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Infective Endocarditis in Patients with Kidney Failure: Chronic Dialysis and Kidney Transplant.

Authors:  James H.E. Ireland; James T. McCarthy
Journal:  Curr Infect Dis Rep       Date:  2003-08       Impact factor: 3.725

10.  Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus.

Authors:  David J Riedel; Elizabeth Weekes; Graeme N Forrest
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.